recently announced that BL-8040 has shown positive pre-clinical
results for the treatment of thrombocytopenia (reduced platelet
production). The data was published in the
British Journal of Hematology
The effect of repeated doses of BL-8040 on healthy and
chemotherapy-induced thrombocytopenic mice was evaluated in the
The number of megakaryocytes within the bone marrow improved
significantly with the repeated administration of BL-8040.
Megakaryocytes are the cells that produce platelets.
Moreover, BL-8040 increased the number of hematopoietic
progenitor cells both in the bone marrow and in the blood. These
cells generate platelets as well as red and white blood cells.
The severity and duration of chemotherapy-induced
thrombocytopenia and cytopenia also declined significantly.
Thrombocytopenia is a frequent side effect of chemotherapy.
The candidate's ability to reduce thrombocytopenia makes it more
attractive for the use of blood cancer treatment.
We remind investors that in Sep 2012, the rights to BL-8040
were in-licensed by the BioLineRxfrom Biokine Therapeutics
BioLineRx' BL-8040 is in a phase II study for the treatment of
acute myeloid leukemia (AML). The multicenter, open-label, phase
II study will evaluate the safety and efficacy of repeated
escalating doses of BL-8040 in adults suffering from
relapsed/refractory AML. Primary endpoints include safety and
tolerability of BL-8040. Secondary endpoints include the
pharmacokinetic profile of the candidate and an efficacy
BioLineRx carries a Zacks Rank #3 (Hold). Currently, companies
Pharmacyclics, Inc. (
Questcor Pharmaceuticals Inc. (
Anika Therapeutics Inc. (
look well-positioned with a Zacks Rank #1 (Strong
ANIKA THERAPEUT (ANIK): Free Stock Analysis
BIOLINE RX LTD (BLRX): Get Free Report
PHARMACYCLICS (PCYC): Free Stock Analysis
QUESTCOR PHARMA (QCOR): Free Stock Analysis
To read this article on Zacks.com click here.